HIGHLIGHTS
SUMMARY
Studies reporting on the safety and effectiveness of reduced doses of DOAC compared with standard doses are limited. A recent patient-level network meta-analyses of RCTs of DOACs versus warfarin in patients with AF reported results that compared to lower-dose DOAC, patients randomized to standard-dose DOAC presented a lower risk of stroke/SE (hazard ratio (HR): 0.76; 95% confidence interval (CI): 0.68-0.86) and of composite efficacy outcome (HR: 0.89; 95% CI: 0.82-0.96). Given that the use of low-dose DOAC is more prevalent . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.